ReutersSeptember 21, 2026
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
Reported by Reuters. Read the original →
What the story says
Novo reports that Cagrilintide (AM833) in combination with semaglutide, referred to as CagriSema, demonstrates greater weight loss compared to a rival product from Lilly in patients with diabetes.
Summarised by a model from Reuters's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).Human · RCT · n=7076 · 2026
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.Human · RCT · n=189 · 2024
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.Human · RCT · n=2713 · 2024
What the headline doesn't tell you
- Cagrilintide (AM833) has 22 studies on file, 5 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.